Huaxi Biotech’s Pilot Platform Receives Five – Star Rating as Part of First Batch of National – Level Bio – Manufacturing Pilot Capacity Building Platforms – 36Kr

Report on Bloomage Biotechnology’s National Pilot Platform Recognition and Alignment with Sustainable Development Goals

Executive Summary

Bloomage Biotechnology (Tianjin) Co., Ltd. has been awarded a “Five-Star” service capacity rating for its biological manufacturing pilot platform. This designation, part of the first batch of national-level recognitions by the Ministry of Industry and Information Technology and the National Development and Reform Commission, highlights the company’s significant contributions to industrial innovation and its alignment with key United Nations Sustainable Development Goals (SDGs), particularly in health, industry, and responsible production.

National Strategy for Industrial Innovation and Sustainable Infrastructure (SDG 9)

Overview of the Pilot Platform Initiative

The national selection of pilot platforms is a strategic measure to implement the “Implementation Opinions on the Innovation and Development of Pilot Testing in the Manufacturing Industry.” The initiative is designed to accelerate the critical transition of scientific and technological achievements from laboratory research to full-scale industrialization. This directly supports the objectives of SDG 9 (Industry, Innovation, and Infrastructure) by building resilient infrastructure, promoting inclusive and sustainable industrialization, and fostering innovation.

Program Objectives

• To cultivate pilot platforms in key industrial tracks and fields based on market demand.
• To bridge the gap between technology R&D, achievement transfer, and commercial application.
• To encourage market-based operations for the sustainable functioning of these platforms.
• To establish leading platforms that serve as exemplars for the entire manufacturing sector.

Platform Assessment and Contribution to Global Goals

“Five-Star” Certification and Core Competencies

Bloomage Biotechnology’s platform achieved the highest “Five-Star” rating, demonstrating exceptional service capabilities. This recognition underscores the platform’s role in advancing several SDGs.

1. SDG 3 (Good Health and Well-being): The platform’s certified excellence in biopharmaceuticals, food additives, and cosmetics directly contributes to public health and well-being by enabling the development of innovative health and personal care products.
2. SDG 9 (Industry, Innovation, and Infrastructure): The platform meets stringent national standards across four key modules: technical equipment, public infrastructure, service capabilities, and intellectual property protection, establishing it as a cornerstone of industrial innovation infrastructure.
3. SDG 12 (Responsible Consumption and Production): By specializing in biological manufacturing and synthetic biology, the platform promotes sustainable production patterns. This approach offers an alternative to traditional chemical processes, potentially reducing waste and environmental impact.

Operational Impact and Economic Contribution (SDG 8)

The platform’s “R&D – Pilot – Industrialization” system provides a robust framework for converting scientific research into viable commercial products, thereby fostering economic growth and creating high-value employment opportunities, in line with SDG 8 (Decent Work and Economic Growth).

• Infrastructure: Equipped with world-class fermentation systems, purification equipment, and 64 flexible pilot production lines.
• Service Scope: Supports strategic emerging industries including medical health, beauty, personal care, and functional food.
• Proven Track Record: Has successfully served over 20 external enterprises and completed more than 30 industrialization projects, shortening the marketization cycle for innovative products.

Future Strategy: Fostering Partnerships for the Goals (SDG 17)

Building a Collaborative Innovation Ecosystem

Bloomage Biotechnology plans to leverage its national platform status to build a comprehensive biotechnology innovation ecosystem. This strategy is centered on collaboration and directly aligns with SDG 17 (Partnerships for the Goals) by fostering multi-stakeholder partnerships to advance sustainable development.

Strategic Commitments

1. Enhance Collaborative Networks: Actively cooperate with upstream and downstream partners to provide systematic solutions and build an industrial ecological alliance.
2. Drive Innovation and Efficiency: Increase R&D investment to improve the efficiency of pilot transformation and accelerate the industrialization of biotechnology.
3. Promote National and Global Health: Contribute to the Healthy China Strategy and the global bio-economy, reinforcing its commitment to SDG 3.
4. Establish Industrial Leadership: Consolidate its technological leadership to help elevate China’s biotechnology industry to a world-class level, thereby strengthening the global capacity for sustainable industrial development (SDG 9).

SDGs Addressed in the Article

SDG 9: Industry, Innovation and Infrastructure

• The article’s core subject is the creation and recognition of a “pilot achievement transformation platform for biological manufacturing.” This platform is a form of specialized infrastructure designed to foster innovation by bridging the gap between laboratory research and industrial-scale production. It directly supports the manufacturing industry, aiming to “accelerate the important process of transforming scientific and technological achievements from the laboratory to industrialization.”

SDG 3: Good Health and Well-being

• The platform’s services and the company’s focus areas are explicitly linked to health. The article states that its service scope covers strategic industries such as “medical and health” and “biopharmaceuticals.” Furthermore, it aims to inject “strong impetus into the implementation of the Healthy China Strategy,” directly connecting its industrial activities to national health objectives.

SDG 17: Partnerships for the Goals

• The article repeatedly emphasizes collaboration. The platform itself is a result of a public-private initiative involving the “Ministry of Industry and Information Technology and the National Development and Reform Commission.” It is designed to deepen “industry-university-research collaborative innovation” and involves active cooperation with “upstream and downstream partners in the industrial chain” to build an “industrial ecological alliance.”

SDG 8: Decent Work and Economic Growth

• The initiative aims to promote economic growth by enhancing industrial capabilities. The platform is intended to contribute to the “high-quality development of the industry” and the “take-off of the bio-economy.” By focusing on a high-value sector like biotechnology and improving the efficiency of industrialization, it supports higher levels of economic productivity.

SDG 12: Responsible Consumption and Production

• The article focuses on “biological manufacturing,” a field often associated with more sustainable production methods compared to traditional chemical synthesis. The platform’s emphasis on “efficient extraction of active substances” and improving “the efficiency of pilot transformation” points towards a more efficient use of resources, which is a key component of sustainable production.

Specific Targets Identified

SDG 9: Industry, Innovation and Infrastructure

1. Target 9.5: Enhance scientific research, upgrade the technological capabilities of industrial sectors. The entire purpose of the pilot platform is to “accelerate the important process of transforming scientific and technological achievements from the laboratory to industrialization.” The article also mentions the company will “continue to increase R & D investment,” directly supporting this target.
2. Target 9.b: Support domestic technology development, research and innovation. The platform is part of a national initiative to cultivate domestic capabilities in manufacturing. It provides “an important support platform for deepening industry-university-research collaborative innovation,” fostering a domestic ecosystem for technological advancement.

SDG 3: Good Health and Well-being

1. Target 3.b: Support the research and development of medicines. The platform’s work in “biopharmaceuticals” and its goal to “shorten the marketization cycle of innovative products” directly supports the R&D and delivery of new medical solutions, contributing to the broader goal of this target.

SDG 17: Partnerships for the Goals

1. Target 17.16: Enhance multi-stakeholder partnerships. The platform is described as a hub for “industry-university-research collaborative innovation” and a catalyst for building an “industrial ecological alliance” with “upstream and downstream partners,” which exemplifies the multi-stakeholder partnership model.
2. Target 17.17: Encourage and promote effective public, public-private partnerships. The selection of Bloomage Biotechnology’s platform by government bodies (“Ministry of Industry and Information Technology and the National Development and Reform Commission”) is a clear example of a public-private partnership designed to achieve national industrial goals.

SDG 8: Decent Work and Economic Growth

1. Target 8.2: Achieve higher levels of economic productivity through technological upgrading and innovation. The article highlights how the platform will “accelerate the industrialization process of biotechnology achievements” and “contribute to the high-quality development of the industry,” which are direct pathways to increasing economic productivity through technological advancement in a high-value sector.

SDG 12: Responsible Consumption and Production

1. Target 12.a: Support developing countries to strengthen their scientific and technological capacity to move towards more sustainable patterns of production. The platform is a concrete example of strengthening technological capacity in “biological manufacturing,” a modern production method. The focus on improving “the efficiency of pilot transformation” aligns with moving towards more sustainable patterns.

Indicators Mentioned or Implied

SDG 9: Industry, Innovation and Infrastructure

• Directly Mentioned Indicator: The company’s commitment to “continue to increase R & D investment” relates to Indicator 9.5.1 (Research and development expenditure as a proportion of GDP).
• Implied Indicators:
  • Number of enterprises served by the platform (The article states it has “served more than 20 external enterprises”).
  • Number of R&D projects successfully industrialized (The article mentions it has “completed more than 30 projects on transforming scientific and technological achievements into industrialization”).
  • Number of national-level pilot platforms established (The article refers to the “first batch of only five national-level units”).

SDG 3: Good Health and Well-being

• Implied Indicator: Number of new products developed and commercialized in the medical, health, and biopharmaceutical sectors. This is implied by the goal to “shorten the marketization cycle of innovative products” and contribute to the “Healthy China Strategy.”

SDG 17: Partnerships for the Goals

• Implied Indicators:
  • Number of active partnerships between industry, universities, and research institutions facilitated by the platform.
  • Number of companies participating in the “industrial ecological alliance.”

SDG 8: Decent Work and Economic Growth

• Implied Indicator: Contribution of the bio-economy to industrial GDP. This is implied by the platform’s aim to help the “bio-economy” to “take-off” and achieve “high-quality development of the industry.”

SDG 12: Responsible Consumption and Production

• Implied Indicator: Measures of resource efficiency in the manufacturing process. This is implied by the stated advantages in “fermentation engineering optimization” and the goal to “improve the efficiency of pilot transformation.”

Summary Table of SDGs, Targets, and Indicators

Source: eu.36kr.com